Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
| ▸ | CCR3 | P51677 | 14/20 | 0.57 |
| ▸ | HTR2A | P28223 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373751 | 0.89 | HTR6 (0.69) | HTR6CCR3HTR2AKCNH2HTR2C | |
| SCHEMBL2564429 | 0.79 | CCR3 (0.59) | HTR6CCR3DRD2 | |
| SCHEMBL3994282 | 0.74 | CCR3 (0.70) | CCR3DRD2 | |
| SCHEMBL7844479 | 0.74 | HTR6 (0.50) | HTR6CCR3HTR2AHTR2C | |
| SCHEMBL1097478 | 0.74 | CCR3 (1.00) | CCR3 | |
| SCHEMBL4001590 | 0.72 | CCR3 (0.69) | CCR3DRD2 | |
| SCHEMBL4078326 | 0.70 | PARP1 (0.48) | HTR6CCR3HTR2AKCNH2HTR2C | |
| SCHEMBL2569896 | 0.68 | HTR6 (0.63) | HTR6HTR2AHTR2C | |
| SCHEMBL2565277 | 0.67 | CCR3 (0.61) | HTR6CCR3 | |
| SCHEMBL30275187 | 0.67 | HTR2A (0.64) | HTR2AHTR2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687294-B1 | NOVEL PIPERIDINE-SUBSTITUTED INDOLES-OR HETERO-DERIVATIVES THEREOF AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR (CCR-3) | BOEHRINGER INGELHEIM INT (DE) | 2014-05-21 | — | — | EP | disclosed |
| EP-1994019-B1 | NOVEL PIPERIDIN - SUBSTITUTED INDOLES AND THEIR USE AS CCR-3 MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2011-11-02 | — | — | EP | disclosed |
| EP-1994019-B1 | NOVEL PIPERIDIN - SUBSTITUTED INDOLES AND THEIR USE AS CCR-3 MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-7759365-B2 | Piperidine-substituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759365-B2 | Piperidine-substituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759365-B2 | Piperidine-substituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7544806-B2 | Piperidine-substituted indoles-or heteroderivatives thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7544806-B2 | Piperidine-substituted indoles-or heteroderivatives thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7544806-B2 | Piperidine-substituted indoles-or heteroderivatives thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| CN-1882565-A | Novel piperidine-substituted indoles-or hetero-derivatives thereof and their use as modulators of chemokine receptor (CCR-3) | BOEHRINGER INGELHEIM INT (DE) | 2006-12-20 | — | — | CN | disclosed |
| US-20060247230-A1 | Novel Piperidine-Substituted Indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-02 | — | — | US | disclosed |
| US-20050153979-A1 | Novel piperidine-substituted indoles-or heteroderivatives thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153979-A1 | Novel piperidine-substituted indoles-or heteroderivatives thereof | CCR3, CCR1, CCR2 | HTR6 208/4885CCR3 1/4885HTR2A 248/4885 |
| US-20060247230-A1 | Novel Piperidine-Substituted Indoles | CCR3, CCR1, CCR2 | HTR6 286/4885CCR3 1/4885HTR2A 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.